Vaccines will boost McKesson

Article Excerpt

MCKESSON CORP. $188 is a buy for aggressive investors. The company (New York symbol MCK; Aggressive Growth Portfolio, Consumer sector; Shares o/s: 191.8 million; Market cap: $36.1 billion; Price-to-sales ratio: 0.1; Dividend yield 0.9%; TSINetwork Rating: Above Average; www.mckesson.com) is the largest wholesale drug distributor in the U.S. and Canada. It also operates drugstores in Europe and North America. In August 2020, the U.S. government selected McKesson as the main distributor of frozen and refrigerated COVID-19 vaccines (manufactured by Pfizer, Moderna, and Johnson & Johnson), and their related supply kits. Thanks to the additional revenue from COVID-19 vaccines, the company expects to earn $16.95 to $17.25 a share for the fiscal year ending March 31, 2021. That’s up from its previous estimate of $16.00 to $16.50. The stock has risen 50% in the past year, but trades at just 11.0 times the midpoint of its new range. The $1.68 dividend yields 0.9%. McKesson is a buy. buy…